PerkinElmer buys preclinical imaging firm
This article was originally published in The Gray Sheet
Executive Summary
Diversified diagnostics and analytical instrumentation company is acquiring in vivo molecular imaging firm VisEn Medical to expand its technologies "downstream into preclinical research undertaken in academic institutes and pharmaceutical companies." Bedford, Mass.-based VisEn makes fluorescence molecular imaging systems and reagents for use in the research of cancer, inflammation, cardiovascular, skeletal and pulmonary diseases. Financial terms of the deal, announced Aug. 3, were not disclosed